The DANCER study (Dose-Ranging Assessment International Clinical Evaluation of Rituximab in RA) evaluated the safety and efficacy in two doses of Rituxan in combination with methotrexate. Also studied was the role of corticosteroids. The DANCER results indicated that Rituxan provided significant improvement in rheumatoid arthritis symptoms compared to placebo, regardless of the dose. Read more about the Rituxan results.
UPDATE: On 03/01/2006, Rituxan (rituximab) was FDA approved to be used in combination with methotrexate to treat rheumatoid arthritis by reducing the signs and symptoms in adult patients who have moderately-to-severely active rheumatoid arthritis and have failed one or more anti-TNF drugs e.g. Enbrel (etanercept), Remicade (infliximab), or Humira (adalimumab).
Comments
No comments yet. Leave a Comment
